240
Participants
Start Date
May 4, 2022
Primary Completion Date
August 30, 2025
Study Completion Date
December 15, 2025
Dupilumab
Dupilumab is a recombinant DNA-derived humanized IgG4ĸ monoclonal antibody that selectively binds to anti IL-4R monoclonal antibody (mAb).
Placebo
The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
RECRUITING
Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute, New York
RECRUITING
Columbia University Medical Center: Division of Pediatric Pulmonology, New York
RECRUITING
Children's National Medical Center: Children's Research Institute, Washington D.C.
RECRUITING
Cincinnati Children's Hospital Medical Center: Asthma Center, Cincinnati
RECRUITING
Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology, Chicago
RECRUITING
Washington University at St. Louis, St Louis
RECRUITING
Children's Hospital Colorado: Allergy Program, Aurora
ACTIVE_NOT_RECRUITING
Boston Children's Hospital: Department of Immunology, Boston
Childhood Asthma in Urban Settings (CAUSE)
UNKNOWN
Regeneron Pharmaceuticals
INDUSTRY
Rho Federal Systems Division, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH